Topical mycophenolate for the treatment of uveitis-associated inflammation

Key Points

• Topical mycophenolate significantly reduces uveitis-associated inflammation, improving visual outcomes.
• A reduction of inflammation markers was observed in 65% of patients within eight weeks of treatment.
• Assessment using intraocular pressure and visual acuity measurements provided key insights into treatment success.
• This method shows potential for lower systemic side effects compared to traditional therapies, warranting further validation.